Biological/Research Material for H1N1 Influenza Virus Vaccine Research


Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice.

The materials can be used for research purposes and in particular in the area of influenza virus vaccines.

The related publications listed below demonstrate the usefulness of this biological material in influenza virus vaccine research.

Potential Commercial Applications: Competitive Advantages:
  • Research reagents useful in research and development in the area of H1N1 Influenza virus vaccines.
 


Development Stage:
Fully developed. The usefulness of the materials has been shown in Dr. Moss' laboratory.

Related Invention(s):
E-552-1982-2


Inventors:

Bernard Moss (NIAID)  ➽ more inventions...

Linda Wyatt (NIAID)  ➽ more inventions...


Intellectual Property:
Research Material - Patent protection is not being pursued for this technology.

Publications:
Sutter G, et al. PMID 7975844
Bender B, et al. PMID 8709274

Licensing Contact:
Benjamin Hurley, Ph.D.
Email: benjamin.hurley@nih.gov
Phone: 240-669-5092

OTT Reference No: E-260-2009-0
Updated: Sep 10, 2015